IDYA News and Press, IDEAYA Biosciences Inc. From 04/01/24

IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , April 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and...

2024-03-12 09:29:51 ET More on Ideaya, Merck, etc. Merck & Co., Inc. (MRK) Management presents at Leerink Partners 2024 Global Biopharma Conference (Transcript) Merck & Co., Inc. (MRK) TD Cowen 44th Annual Healthcare Conference (Transcript) Merck: A Great Div...

IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer PR Newswire ­Trial will evaluate IDE161, IDEAYA's investigational PARG inhibitor, in combination with KEYTRUDA ® ...

2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

2024-03-08 12:11:45 ET More on IDEAYA, Immunocore, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Ideaya Biosciences: A Strong Bet In Targeted Oncology Immunocore Holdings: Vulnerable To Profit Taking After Big Rally Immunocore to work w...

IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events PR Newswire SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development ...

2024-03-02 18:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-21 11:30:02 ET RBC Capital analyst issues BUY recommendation for IDYA on February 21, 2024 11:01AM ET. The previous analyst recommendation was Buy. IDYA was trading at $44.24 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...

2024-02-20 09:52:37 ET More on IDEAYA Biosciences Ideaya Biosciences: A Strong Bet In Targeted Oncology Ideaya Biosciences Stock: An Opportunity Missed (Rating Downgrade) Seeking Alpha’s Quant Rating on IDEAYA Biosciences Historical earnings data for I...

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update PR Newswire Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma (UM) in mid-2024, including from the Phase 2...